Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 551 to 600 of 7997 results

  1. Methods research areas

    NICE priority methodological research areas.

  2. Evidence and best practice resources

    Find health, social care and public health evidence and best practice resources.

  3. Virtual reality technologies for treating agoraphobia or agoraphobic avoidance: early value assessment (HTE15)

    Early value assessment (EVA) guidance on virtual reality technologies for treating agoraphobia or agoraphobic avoidance....

  4. Extracorporeal carbon dioxide removal for acute respiratory failure (IPG776)

    Evidence-based recommendations on extracorporeal carbon dioxide removal for acute respiratory failure. This involves taking blood out of the circulatory system and passing it across a synthetic membrane that allows some of the carbon dioxide in the blood to be removed. The blood is then returned to the circulatory system.

  5. Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments (TA930)

    Evidence-based recommendations on lutetium-177 vipivotide tetraxetan (Pluvicto) for treating prostate-specific membrane antigen-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments in adults.

  6. Biodegradable subacromial spacer insertion for rotator cuff tears (IPG775)

    Evidence-based recommendations on biodegradable subacromial spacer insertion for rotator cuff tears. This involves inserting a balloon-shaped device between the top of the shoulder blade and the upper arm bone to reduce pain and improve shoulder function.

  7. Using our guidance

    Support for voluntary and community sector organisations using NICE guidance

  8. Recognising and preventing delirium

    NICE's quick guide on recognising and preventing delirium

  9. Environmental sustainability

    NICE is committed to supporting the national agenda for achieving a sustainable health and care system.

  10. Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer (CG164)

    This guideline covers care for people with a family history of breast, ovarian or another related (prostate or pancreatic) cancer. It aims to improve the long-term health of these families by describing strategies to reduce the risk of and promote early detection of breast cancer (including genetic testing and mammography). It also includes advice on treatments (tamoxifen, raloxifene) and surgery (mastectomy).

  11. What is the effectiveness and cost effectiveness of immunotherapy in people with stage IIIA-N2 non‑small‑cell lung cancer following multimodality treatment including surgery?

    Recommendation ID NG122/01 Question What is the effectiveness and cost effectiveness of immunotherapy in people with stage IIIA-N2 non‑small‑cell

  12. Flow transcranial direct current stimulation for treating depression (MIB324)

    May 2024: This medtech innovation briefing has been withdrawn. This is because the evidence for the technology has changed since it was published. NHS England no longer fund NICE to produce or maintain medtech innovation briefings, so these are no longer being reviewed.

  13. Indicator advisory committee members

    Biographies and interests register for the indicator advisory committee

  14. Board committees

    Our board has 2 sub-committees: the audit and risk assurance committee and the remuneration committee . Audit and risk assurance committee The audit

  15. Early access to medicines scheme (EAMS)

    A joint NICE and NHS England meeting can help to ensure you're ready for NHS patient access and subsequent NICE appraisal

  16. A new model for evaluating and purchasing antimicrobials in the UK

    Antimicrobial resistance (AMR) is an urgent global challenge. It causes around 700,000 deaths each year globally . That number is predicted to rise to

  17. Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine (TA928)

    Evidence-based recommendations on cabozantinib (Cabometyx) for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine, in adults.

  18. Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (TA929)

    Evidence-based recommendations on empagliflozin (Jardiance) for treating chronic heart failure with preserved or mildly reduced ejection fraction in adults.

  19. Acute respiratory infection in over 16s: initial assessment and management including virtual wards (hospital at home) (QS210)

    This quality standard covers the initial assessment and management of suspected acute respiratory infection in over 16s, including acute respiratory infection virtual wards.

  20. NICE health technology evaluations: the manual (PMG36)

    This guide describes the methods and processes, including expected timescales, that NICE follows when carrying out health technology evaluations. The methods and processes are designed to produce robust guidance for the NHS in an open, transparent and timely way, with appropriate contribution from stakeholders. Organisations invited to contribute to health technology evaluation development should read this manual in conjunction with the NICE health technology evaluation topic selection: the manual. All documents are available on the NICE website.

  21. Jaundice in newborn babies under 28 days (CG98)

    This guideline covers diagnosing and treating jaundice, which is caused by increased levels of bilirubin in the blood, in newborn babies (neonates). It aims to help detect or prevent very high levels of bilirubin, which can be harmful if not treated.

  22. Cancer: bowel screening (60 to 74 years) (IND64)

    This indicator covers the proportion of eligible people aged 60 to 74 years whose record shows a bowel screening test has been performed within the last 2.5 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG83

  23. Cancer: invasive cancer diagnosed via emergency routes (IND1)

    This indicator covers the proportion of invasive cases of cancer diagnosed via an emergency route. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCC01

  24. Cancer: faecal immunochemical testing (IND267)

    This indicator covers the percentage of urgent suspected colorectal cancer referrals accompanied by a faecal immunochemical test (FIT) result, with the result recorded in the 21 days leading up to the referral. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM251.

  25. Learning disabilities: health checks, action plans and ethnicity (IND266)

    This indicator covers the percentage of patients on the learning disability register, who: received a learning disability health check and had a completed health action plan in the preceding 12 months and, have a recording of ethnicity. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM250

  26. Learning disabilities: health checks and action plans (IND265)

    This indicator covers the percentage of patients on the learning disability register who received a learning disability health check and had a completed health action plan in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM249

  27. Pneumonia in adults: diagnosis and management (CG191)

    This guideline was developed before the COVID-19 pandemic. It covers diagnosing and managing pneumonia in adults who do not have COVID-19. It aims to improve accurate assessment and diagnosis of pneumonia to help guide antibiotic prescribing and ensure that people receive the right treatment.

  28. Ranibizumab for treating diabetic macular oedema (TA274)

    Evidence-based recommendations on ranibizumab (Lucentis) for treating diabetic macular oedema in adults.

  29. Tirzepatide for treating type 2 diabetes (TA924)

    Evidence-based recommendations on tirzepatide (Mounjaro) for type 2 diabetes in adults.

  30. Mirikizumab for treating moderately to severely active ulcerative colitis (TA925)

    Evidence-based recommendations on mirikizumab (Omvoh) for treating moderately to severely active ulcerative colitis in adults.

  31. Baricitinib for treating severe alopecia areata (TA926)

    Evidence-based recommendations on baricitinib (Olumiant) for treating severe alopecia areata in adults.

  32. Vaginal transluminal endoscopic hysterectomy and adnexal surgery for benign gynaecological conditions (IPG774)

    Evidence-based recommendations on vaginal transluminal endoscopic hysterectomy and adnexal surgery for benign gynaecological conditions. This involves removing the uterus (womb), and sometimes the fallopian tubes and ovaries, through the vagina.

  33. Evidence standards framework (ESF) for digital health technologies

    NICE standards for innovators of digital health technologies and NHS commissioners

  34. Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable (TA917)

    Evidence-based recommendations on daratumumab (Darzalex) with lenalidomide and dexamethasone for untreated multiple myeloma in adults, when a stem cell transplant is unsuitable.

  35. Charging procedure: technology appraisal and highly specialised technologies evaluations

    Introduction In accordance with UK Statutory Instrument 2018 No.1322 , NICE must recover its costs for producing Technology Appraisals (TA) or Highly

  36. Tabelecleucel for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus (terminated appraisal) (TA923)

    NICE is unable to make a recommendation on tabelecleucel (Ebvallo) for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus. This is because Pierre Fabre Ltd did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Sections for TA923

  37. Percutaneous deep venous arterialisation for chronic limb-threatening ischaemia (IPG773)

    Evidence-based recommendations on percutaneous deep venous arterialisation for chronic limb-threatening ischaemia. This involves making a hole between a blocked artery and a vein, allowing the blood to flow into the leg beyond the blockage.

  38. Rimegepant for treating migraine (TA919)

    Evidence-based recommendations on rimegepant (Vydura) for the acute treatment of migraine in adults.

  39. Ruxolitinib for treating polycythaemia vera (TA921)

    Evidence-based recommendations on ruxolitinib (Jakavi) for polycythaemia vera in adults.

  40. Tofacitinib for treating active ankylosing spondylitis (TA920)

    Evidence-based recommendations on tofacitinib (Xeljanz) for treating active ankylosing spondylitis.

  41. Stroke and ischaemic attack: early supported discharge (IND32)

    This indicator covers the proportion of people who had a stroke that are supported by a skilled stroke early supported discharge team. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG49

  42. Stroke and ischaemic attack: review 6 months after discharge (IND31)

    This indicator covers the proportion of people who had a stroke who are reviewed within 6 months of being discharged from hospital. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG48

  43. Stroke and ischaemic attack: care plan on discharge (IND30)

    This indicator covers the proportion of people with stroke who receive joint health and social care plans on discharge from hospital. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG47

  44. Stroke rehabilitation in adults (NG236)

    This guideline covers rehabilitation after stroke for over 16s. It aims to ensure people are assessed for common problems and conditions linked to stroke, and get the care and therapy they need. It includes recommendations on the organisation and delivery of rehabilitation in hospital and the community.

  45. Daridorexant for treating long-term insomnia (TA922)

    Evidence-based recommendations on daridorexant (QUVIVIQ) for treating long-term insomnia in adults.

  46. Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (TA927)

    Evidence-based recommendations on glofitamab (Columvi) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments.

  47. Public board meetings

    Wednesday 19 July 2023 at 1:30pm via Zoom. Agenda Apologies for absence To receive any apologies for absence. Declarations of interest To

  48. Virtual ward platform technologies for acute respiratory infections (HTE13)

    Early value assessment (EVA) guidance on virtual ward platform technologies for acute respiratory infections....

  49. Thyroid disease: assessment and management (NG145)

    This guideline covers investigating all suspected thyroid disease and managing primary thyroid disease (related to the thyroid rather than the pituitary gland). It does not cover managing thyroid cancer or thyroid disease in pregnancy. It aims to improve quality of life by making recommendations on diagnosis, treatment, long-term care and support.

  50. Social care trainers' resource

    Training resources for those working in social care